FGFR2 and cholangiocarcinoma: Findings from this retrospective, primarily community oncology-based physician-abstracted medical chart review study demonstrate the demographics, clinical characteristics, FGFR2 testing patterns, treatment patterns, and clinical outcomes of 120 patients treated with pemigatinib for unresectable, locally advanced or metastatic CCA as a part of routine clinical care.